Impact Factor
3.44
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.73
891 total citations
h5-index
38
h5 depth signal
Cited share
63.5%
217 of 342
Total citations
891
Citation footprint
Metric signal
2.94
External metric anchor
Self-citation
10.0%
89 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
607
United States
364
Germany
170
Australia
166
China
153
Citing Fields of Research
Allergies
1,777
Immunology
350
Dermatology
55
Respiratory Support
43
Genetics & Genomics
41
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
10,591
Articles tracked across the journal lifetime
Indexed publication set
342
217 cited publications
Last 12 months
295
24.6 publications/month
Open access share
41.7%
123 OA publications in the last year
Leading citing country
United Kingdom
607 citing publications
Leading citing field
Allergies
1,777 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v19n1,Jan. 1989-
v19n1,Jan. 1989-
Active Coverage
Research Focus & Classification
Indexed Subjects
Allergies
Issuing & Sponsoring Bodies
Contributor
British Society for Allergy and Clinical Immunology
Broad Categories
Allergy and Immunology
Allergies
MeSH Descriptors
Hypersensitivity
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/cea.70451
Open DOI
Allergen‐Sensitised Whole Blood Samples for Quality Control and Benchmarking of Basophil Activation Tests
Summary: In vitro blood sensitisation with allergen‐specific IgE enables on‐demand control samples for BAT quality control. Applications in development, quality control and benchmarking of BAT reagents, allergen preparations and immunomo...
02
DOI 10.1111/cea.70450
Open DOI
Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX ‐1/2 Phase 3 Studies
Summary: We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.
03
DOI 10.1111/cea.70454
Open DOI
Yeast Surface Display for Efficient Generation of Nanobody‐Based Human IgG Targeting the 11S Globulin From Hazelnut, Cor a 9
Summary: Yeast surface display allows efficient selection of nanobodies and generation of IgG‐like antibody formats. Antibodies targeting Cor a 9 exhibit cross‐reactivity with tree nuts and peanut, not walnut.
04
DOI 10.1111/cea.70458
Open DOI
Siglec Expression Patterns in Food Allergy Reveal Altered Intensity but Not Frequency
Summary: Siglecs are diversely expressed among PBMCs, with the broadest expression on antigen‐presenting cells. Food‐allergic individuals with objective symptoms show lower relative expression of Siglecs compared to those with subjective...
05
DOI 10.1111/cea.70452
Open DOI
A Penicillin Allergy Clinical Decision Rule Performs Differently in Immediate and Delayed Hypersensitivity
Summary: PEN‐FAST showed good overall discrimination in routine specialist penicillin allergy assessment. Discrimination was higher for immediate than delayed penicillin hypersensitivity.
06
DOI 10.1111/cea.70455
Open DOI
Plasma Resolvin D2 Is Elevated and Lipoxin A 4 Is Reduced in Atopic Dermatitis: A Candidate Lipid Mediator Imbalance
Summary: Plasma lipid mediators are broadly suppressed in atopic dermatitis, except resolvin D2, which is elevated. Lipoxin A 4 is reduced in atopic dermatitis and warrants investigation as an anti‐inflammatory target.
07
DOI 10.1111/cea.70449
Open DOI
PROTEGO Study Protocol: A Cluster Randomised Crossover Trial of Vernix Caseosa Retention for Primary Prevention of Atopic Dermatitis
Summary: PROTEGO is a Chilean cluster‐randomised crossover trial of vernix caseosa retention to prevent atopic dermatitis. 1383 mother‐infant dyads will be enrolled and followed for atopic dermatitis until 12 months.
08
DOI 10.1111/cea.70448
Open DOI
Tryptase Locus Variation Contributes to Normal‐Range Basal Serum Tryptase Variability and Is Associated With Anaphylaxis
Background: Increased basal serum tryptase level (BST) is associated with anaphylaxis. In the absence of clonal mast cell disease and hereditary α‐tryptasemia (HαT), the contribution of the tryptase locus variation to BST and anaphylaxis...
09
DOI 10.1111/cea.70445
Open DOI
Cochrane Corner: Probiotics in Infants for Prevention of Allergic Disease
10
DOI 10.1111/cea.70447
Open DOI
Frequency and Timing of Specialized Formula Prescriptions for Children Under 2 Years
Background: Infants with non‐specific symptoms are sometimes labelled as cow's milk allergic and managed with specialized formula. These products differ from standard infant formula in protein and carbohydrate source, typically containin...
Bibliographical & Catalog Notes
Title from cover.
Some vols. have supplements.
Print issues ceased with v. 45, no. 12 (Dec. 2015).
Also issued online.
Vol. 21, no. 1 (JAN 1991)19910912 Notice published Printed on acid-free paper